<DOC>
	<DOCNO>NCT00772863</DOCNO>
	<brief_summary>The purpose study assess efficacy safety treatment .</brief_summary>
	<brief_title>Efficacy Safety Subsequent Cisplatin Docetaxel Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically/cytologically confirm , optimally debulked stage IIIIV epithelial ovarian cancer exclude clear cell histology . ECOG Performance Status 02 No prior chemotherapy malignancy , Acceptable hematological profile ( define leukocyte count ≥ 3000/mm3 , platelet count ≥ 100.000mm3 Hb ≥ 9g/100mL ) , adequate renal function ( define serum creatinine ≤ 1.5mg/dl creatinine clearance formulation ≥ 60 mL/min ) , hepatic function ( define bilirubin ≤ 1.5 x maximum normal value even hepatic metastasis ; transaminase ( ALT , AST ) ≤ 1.5 x maximum normal value ; alkaline phosphatase ≤ 2.5 x maximum normal value , except case bone metastasis ) Concomitant use another anticancer therapy Unstable medical condition make patient unable take part clinical study ( congestive heart failure , serious arrythmia , uncontrolled diabetes mellitus ) , history myocardial infarction within last 3 month , massive pleural , peritoneal pericardial effusion ; presence serious uncontrolled infection . Presence tumours different basal cell carcinoma skin . Pregnancy breastfeed . In woman childbearing potential men , adequate contraceptive method must use Social psychological condition render patient inadequate followup study Contraindication study drug ( e.g . history hypersensitivity ingredient study drug ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>